Albany, NY -- (SBWIRE) -- 05/22/2020 -- Refractory Angina Market Insights, Epidemiology and Market Forecast-2030

(Albany, US) DelveInsight launched a new report on Refractory Angina Market Insights, Epidemiology and Market Forecast-2030

Some of the key facts of the report
1. The total Refractory Angina prevalent cases in 7MM were 29,17,196 in 2017.
2. The United States reported for most prevalent cases of Refractory Angina in 7MM with 19,05,602 cases in 2017.
3. Among EU5 countries, Germany accounted for the most number of prevalent cases of Refractory Angina with 5,13,896 cases in 2017.

Key benefits of the report
1. Refractory Angina Market report covers a descriptive overview and comprehensive insight of the Refractory Angina epidemiology and Refractory Angina market in the 7 MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
2. Refractory Angina market report provides insights into the current and emerging therapies.
3. Refractory Angina market report provides a global historical and forecasted market covering drug outreach in 7 MM.
4. Refractory Angina market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Refractory Angina market.

Request for sample pages

Refractory Angina is a chronic disease characterized by the presence of persistent Angina. Despite continuous developments in Coronary Artery Disease (CAD) management, particularly in the aged population, the number of patients suffering from Refractory Angina is correlated to the healthcare expenses.

Currently, there are several methods for Refractory Angina treatment, which involves pharmacological treatments approaches, coronary sinus reducer. Several non- invasive methods are also available to treat this disease, like External Enhanced Counter Pulsation (EECP), extracorporeal shockwave therapy (ESWT), neuromodulation. Pragmatic rehabilitation is also a critical approach to promote patients to manage their chest pain.

There is no significant pharmacologic approved therapy to improve quality of life in patients of Refractory Angina, but a significant amount of evidence exists in the literature that supports the use of pharmacologic treatment in the Stable Angina. Beta-blockers and Calcium Channel Antagonists like Nicorandil (K-ATP - channel opener), Ivabradine (If current inhibitor), Trimetazidine (Reversible 3-ketoacyl-thiolase inhibitor), Ranolazine, Fasudil/hydroxyfasudil (Rho-kinase inhibitor) are few mainstay medical treatment for Angina. Furthermore, the European Society of Cardiology guidelines now consider ivabradine, nicorandil, or ranolazine with long-acting nitrates as second-line therapy for patients with persistent Angina, according to heart rate, blood pressure, and tolerance.

Several drugs and therapies are suggested as first and the second line of treatment, however, not all of the treatments mentioned above were formally suggested for the disease. Development of Refractory Angina -specific clinical guidelines is needed. Refractory Angina market is expected to experience growth in the coming years as there are few drugs lined up and are expected to launch during the forecast period [2020–2030].

The launch of the emerging therapies is expected to significantly impact Refractory Angina treatment scenario in the upcoming years:-
Drugs covered
1. IMB-101
2. Auto CD34+ Cells
3. Generx
4. XC001
And many others

The key players in Refractory Angina market are:
1. Imbria Pharmaceuticals
2. Caladrius Biosciences, Inc
3. Angionetics Inc.
4. XyloCor Therapeutics, Inc.
And many others

Table of contents
1 Key Insights
2 Executive Summary of Refractory Angina
3 SWOT Analysis for Refractory Angina
4 Refractory Angina Market Overview at a Glance
5 Refractory Angina Disease Background and Overview
6 Refractory Angina Epidemiology and Patient Population
7 Refractory Angina Epidemiology Assumptions and Rationale - 7MM
8 Country Wise-Epidemiology of Refractory Angina
8.1. The United States
8.2. Germany
8.3. France
8.4. Italy
8.5. Spain
8.6. The United Kingdom
8.7. Japan
9 Refractory Angina Treatment
10 Unmet Needs
11 Case Studies
12 Organizations related with Refractory Angina
13 Refractory Angina Emerging Therapies
13.1. IMB-101: Imbria Pharmaceuticals
13.2 Auto CD34+ Cells: Caladrius Biosciences, Inc.
13.3 Generx: Angionetics Inc.
13.4 XC001: XyloCor Therapeutics, Inc.
14 Refractory Angina 7 Major Market Analysis
15 United States
16 EU5 Countries
16.1. Germany
16.2. France
16.3. Italy
16.4. Spain
16.5. United Kingdom
17 Japan
18 Market Drivers
19 Market Barriers
20 Appendix
21 DelveInsight Capabilities
22 Disclaimer
23 About DelveInsight

About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.

Contact us:
info@delveinsight.com
+919650213330
SOURCE DelveInsight